DEALS

India International Exchange. EXIM opened the new year of 2023 for the debt markets for Indian issuers with its maiden benchmarksized sustainability -10year US$ bonds under its Environmental, Social and Governance Framework. The transaction is a debut/maiden sustainability notes offering by EXIM, which has the same rating as that of the Government of India. This issuance makes EXIM the largest ever single tranche IG ESG issuer out of India. Partner Dina Wadia, supported by partner Uttara Kolhatkar, led the firm’s team in the transaction.

K&L Gates has advised Aigens Holdings, an innovative food and beverage omni-channel SaaS technology company, on its Series A financing led by Ant Group. Velocity Ventures, Phillip Private Equity and Prizm Ventures also participated in the Series A financing. Aigens plans to use the proceeds from the Series A financing to accelerate its expansion across the Asia-Pacific region, and help more restaurants digitalise and enhance their competitiveness. Founded in 2012, Aigens was the first to introduce QR code ordering technology to Hong Kong, Singapore and Malaysia. The company operates in 14 markets and serves more than 4,000 restaurant outlets, including global and regional names like Jollibee Group, Burger King, Starbucks, Shake Shack and Pizza Hut. Aigens processes over US$1.5 billion in GMV and 140 million orders annually. Ant Group, the fintech arm of the e-commerce giant Alibaba, is a world-leading financial services provider to consumers and small businesses, and owns China’s largest digital payment platform Alipay, which serves over one billion users and 80 million merchants. Corporate partner Willian Ho led the firm’s team in the transaction.

Khaitan & Co has advised India-listed Eris Lifesciences on the Rs3.4 billion (US41$m) acquisition by its wholly-owned subsidiary, Eris Oaknet Healthcare, of a part of the dermatology portfolio of Glenmark Pharmaceuticals, via the acquisition of nine trademarks, along with their applicable line extensions. A pharmaceutical company with a pure-play domestic branded formulations business model, Eris Lifesciences has established a leading presence in its core cardio-metabolic franchise in just 15 years from inception, and is also successfully diversifying its business with three emerging therapies (Dermatology, Neuropsychiatry and Gynaecology). Eris Oaknet Healthcare focuses on the dermatology segment business of Eris Lifesciences. This transaction helps augment and expand the business of Eris Oaknet Healthcare by way of expansion in product offerings. Partner Kalpana Unadkat, supported by partners Arindam Ghosh and Shailendra Bhandare, led the